IN2015DN03190A - - Google Patents
Info
- Publication number
- IN2015DN03190A IN2015DN03190A IN3190DEN2015A IN2015DN03190A IN 2015DN03190 A IN2015DN03190 A IN 2015DN03190A IN 3190DEN2015 A IN3190DEN2015 A IN 3190DEN2015A IN 2015DN03190 A IN2015DN03190 A IN 2015DN03190A
- Authority
- IN
- India
- Prior art keywords
- amino
- esrd
- methylpyridin
- pyrazolo
- ethoxyethyl
- Prior art date
Links
- ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-n-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 201000000523 end stage renal failure Diseases 0.000 abstract 2
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717429P | 2012-10-23 | 2012-10-23 | |
| PCT/IB2013/059239 WO2014064566A1 (en) | 2012-10-23 | 2013-10-09 | Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03190A true IN2015DN03190A (enExample) | 2015-10-02 |
Family
ID=49765599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3190DEN2015 IN2015DN03190A (enExample) | 2012-10-23 | 2013-10-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150274735A1 (enExample) |
| EP (1) | EP2911672A1 (enExample) |
| JP (1) | JP2015534977A (enExample) |
| KR (1) | KR20150056853A (enExample) |
| CN (1) | CN104755086A (enExample) |
| AU (1) | AU2013336293B2 (enExample) |
| BR (1) | BR112015008380A2 (enExample) |
| CA (1) | CA2888160A1 (enExample) |
| HK (1) | HK1211850A1 (enExample) |
| IL (1) | IL238374A0 (enExample) |
| IN (1) | IN2015DN03190A (enExample) |
| MX (1) | MX2015005004A (enExample) |
| RU (1) | RU2015115005A (enExample) |
| SG (1) | SG11201502286XA (enExample) |
| WO (1) | WO2014064566A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101939328B1 (ko) * | 2012-12-21 | 2019-01-16 | 주식회사 엘지화학 | 신규한 구조를 가지는 중공사막 및 그 제조 방법 |
| JP7573272B2 (ja) | 2019-02-15 | 2024-10-25 | 国立大学法人東北大学 | １，３－ジオキソラン誘導体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| ES2357120T3 (es) * | 2005-05-12 | 2011-04-18 | Pfizer, Inc. | Formas cristalinas anhidra de n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-carbonil)metanosulfonamida. |
| NL2000291C2 (nl) * | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
-
2013
- 2013-10-09 RU RU2015115005A patent/RU2015115005A/ru not_active Application Discontinuation
- 2013-10-09 CN CN201380055135.1A patent/CN104755086A/zh active Pending
- 2013-10-09 SG SG11201502286XA patent/SG11201502286XA/en unknown
- 2013-10-09 WO PCT/IB2013/059239 patent/WO2014064566A1/en not_active Ceased
- 2013-10-09 MX MX2015005004A patent/MX2015005004A/es unknown
- 2013-10-09 IN IN3190DEN2015 patent/IN2015DN03190A/en unknown
- 2013-10-09 US US14/434,236 patent/US20150274735A1/en not_active Abandoned
- 2013-10-09 HK HK15112752.6A patent/HK1211850A1/xx unknown
- 2013-10-09 BR BR112015008380A patent/BR112015008380A2/pt not_active IP Right Cessation
- 2013-10-09 CA CA 2888160 patent/CA2888160A1/en not_active Abandoned
- 2013-10-09 JP JP2015537386A patent/JP2015534977A/ja active Pending
- 2013-10-09 EP EP13805563.7A patent/EP2911672A1/en not_active Withdrawn
- 2013-10-09 KR KR1020157010146A patent/KR20150056853A/ko not_active Ceased
- 2013-10-09 AU AU2013336293A patent/AU2013336293B2/en not_active Expired - Fee Related
-
2015
- 2015-04-19 IL IL238374A patent/IL238374A0/en unknown
-
2016
- 2016-01-21 US US15/002,530 patent/US20160136170A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150056853A (ko) | 2015-05-27 |
| CA2888160A1 (en) | 2014-05-01 |
| JP2015534977A (ja) | 2015-12-07 |
| EP2911672A1 (en) | 2015-09-02 |
| SG11201502286XA (en) | 2015-05-28 |
| CN104755086A (zh) | 2015-07-01 |
| IL238374A0 (en) | 2015-06-30 |
| AU2013336293B2 (en) | 2016-05-12 |
| AU2013336293A1 (en) | 2015-04-09 |
| HK1211850A1 (en) | 2016-06-03 |
| US20150274735A1 (en) | 2015-10-01 |
| US20160136170A1 (en) | 2016-05-19 |
| RU2015115005A (ru) | 2016-12-20 |
| MX2015005004A (es) | 2015-07-17 |
| WO2014064566A1 (en) | 2014-05-01 |
| BR112015008380A2 (pt) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215253A1 (zh) | 作为激酶抑制剂的吡咯并嘧啶化合物 | |
| ZA202502152B (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| HK1203489A1 (en) | Purinone compounds as kinase inhibitors | |
| EA201491287A1 (ru) | Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций | |
| UA115677C2 (uk) | ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ | |
| MY191669A (en) | Pyrazolyl quinoxaline kinase inihibitors | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX357043B (es) | Inhibidores selectivos de pi3k delta. | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IN2014DN10386A (enExample) | ||
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12014502294A1 (en) | Triazolo compounds as pde10 inhibitors | |
| EA201391440A1 (ru) | Производные пиразолопиримидина | |
| WO2012145575A3 (en) | Therapy for leukemia | |
| IN2015DN03190A (enExample) | ||
| EA201590752A1 (ru) | Препараты производных пиримидиндиона | |
| MX2015015845A (es) | Derivados de pirimidin-4-il)-oxi)-1h-indol-1-carboxamida y uso de los mismos. | |
| UA110910C2 (uk) | Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти) |